The estimated Net Worth of Kevin Patrick Danahy is at least $615 mil dollars as of 16 November 2023. Kevin Danahy owns over 5,393 units of Pulse Biosciences Inc stock worth over $615,103 and over the last 3 years Kevin sold PLSE stock worth over $0.
Sign up
Kevin Danahy PLSE stock SEC Form 4 insiders trading
Kevin has made over 2 trades of the Pulse Biosciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Kevin bought 5,393 units of PLSE stock worth $35,162 on 16 November 2023.
The largest trade Kevin's ever made was buying 6,500 units of Pulse Biosciences Inc stock on 30 September 2022 worth over $14,950. On average, Kevin trades about 1,321 units every 46 days since 2022. As of 16 November 2023 Kevin still owns at least 35,887 units of Pulse Biosciences Inc stock.
You can see the complete history of Kevin Danahy stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Kevin Danahy's mailing address?
Kevin's mailing address filed with the SEC is C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD, CA, 94545.
Insiders trading at Pulse Biosciences Inc
Over the last 8 years, insiders at Pulse Biosciences Inc have traded over $0 worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth $194,618,110 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, eManmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of $6,179,107. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth $85,600.
What does Pulse Biosciences Inc do?
pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and
What does Pulse Biosciences Inc's logo look like?
Complete history of Kevin Danahy stock trades at Pulse Biosciences Inc
Pulse Biosciences Inc executives and stock owners
Pulse Biosciences Inc executives and other stock owners filed with the SEC include:
-
Sandra Gardiner,
Chief Financial Officer, Executive Vice President - Finance, Treasurer, Secretary -
Darrin Uecker,
President, Chief Executive Officer, Director -
Darrin R. Uecker,
Pres, CEO & Director -
Sandra A. Gardiner,
Exec. VP of Fin. & Admin., CFO, Sec. and Treasurer -
Mitchell Levinson,
Independent Director -
Edward A. Ebbers,
Exec. VP & GM of Dermatology -
Edward Ebbers,
Executive Vice President, General Manager - Dermatology -
Manmeet Soni,
Independent Director -
Robert Duggan,
Independent Chairman of the Board -
Kenneth Clark,
Independent Director -
Mahkam Zanganeh,
Independent Director -
Mitchell E. Levinson,
Chief Strategy Officer & Director -
David Danitz,
Sr. VP of Engineering -
Patty Perla,
VP of HR -
Dr. Holly Hartman Ph.D., J.D.,
VP of Bus. Devel. & Corp. Strategy -
Dr. Richard Nuccitelli Ph.D.,
Chief Science Officer -
Thierry B. Thaure,
Director -
Robert J. Greenberg,
Director -
Robert Levande,
Director -
Brian B Dow,
CFO & SVP Admin. and Finance -
Thomas J M D Fogarty,
Director -
Burke Thomas Barrett,
President and CEO -
Ed Ebbers,
EVP & GM, Dermatology -
Den Broek Richard Van,
Director -
Laureen Debuono,
Director -
Shelley D Spray,
Director -
Kevin Patrick Danahy,
Chief Commercial Officer -
Paul A Laviolette,
Director